Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Source: SeekingAlpha
2026-02-26 14:36:15 ET
More on Bayer
- Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention - Slideshow
- Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
- Bayer sues Johnson & Johnson over prostate cancer drug claims
- Bayer stumbles as investors question plan to settle Roundup litigation
Read the full article on Seeking Alpha
For further details see:
Bayer says Xofigo/Xtandi combo shows overall survival benefit in prostate cancer
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.75% G/L:
$14.724 Last:
57,125 Volume:
$14.82 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
